Aurinia Pharmaceuticals (AUPH) Operating Expenses (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Operating Expenses data on file, last reported at $36.3 million in Q1 2026.

• Quarterly Operating Expenses fell 10.67% year-over-year to $36.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $173.8 million (down 19.86% YoY) and the FY2025 annual result came in at $178.1 million, down 25.72% from the prior year.
• Operating Expenses eased to $36.3 million in Q1 2026, from $43.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $74.8 million in Q4 2023 to a low of $36.3 million in Q1 2026.
• A 5-year average of $56.9 million and a median of $58.7 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses surged 32.25% — and 2025, when it plunged 36.09%.
• Tracing AUPH's Operating Expenses over 5 years: stood at $56.5 million in 2022, then surged by 32.25% to $74.8 million in 2023, then dropped by 17.7% to $61.5 million in 2024, then retreated by 28.7% to $43.9 million in 2025, then decreased by 17.3% to $36.3 million in 2026.
• The last three Operating Expenses figures came in at $36.3 million (Q1 2026), $43.9 million (Q4 2025), and $43.7 million (Q3 2025), per Business Quant data.